nacubactam
Small moleculeexperimental
Clinical trial activity
6 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
2
Phase 3
2
Phase 4
0
Earliest trial started Oct 31, 2016 (NCT02972255)
Timeline
Indications
Mechanism of action
- ADC-14 proteinINHIBITOR
adc-14 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
NCCONC(=O)[C@@H]1CC[C@@H]2CN1C(=O)N2OS(=O)(=O)O- Mol. weight
- 324.32 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3989959 ↗
Also known as
- nacubactam
- nacubactam
- ro7079901
- ro7079901
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05905055 | Phase 3 | Sep 22, 2023 | Meiji Seika Pharma Co., Ltd. |
| NCT05887908 | Phase 3 | May 23, 2023 | Meiji Seika Pharma Co., Ltd. |
| NCT03182504 | Phase 1 | Jun 15, 2017 | Roche |
| NCT03174795 | Phase 1 | Jun 7, 2017 | Roche |
| NCT02975388 | Phase 1 | Dec 31, 2016 | Roche |
| NCT02972255 | Phase 1 | Oct 31, 2016 | Roche |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Roche | For profit | 4 | 4 | 1 | 2016 |
| Meiji Seika Pharma Co., Ltd. | For profit | 2 | 2 | 1 | 2023 |
2 organizations
Page 1 / 1